The management behind the molecules: pharmaceutical CEOs outline their key revenue drivers. (Focus 2003: Active Pharmaceutical Ingredients).

Chemical Market Reporter, March, 2003 by Van rnum, Patricia

Many concede that 2003 will be a transition year for the major pharmaceutical companies in terms of new drug development and product launches. That will put an even greater pressure on companies' mainstay products as pharmaceutical executives work to maintain revenues and meet financial expectations for their companies in 2003.

Pfizer Perhaps the best-positioned company in terms of marketed products is Pfizer, which will be adding to its commercial arsenal through the pending S60 billion acquisition of Pharmacia. "On a standalone basis, we are exceptionally well positioned to maintain our strong momentum in 2003 and beyond," says Hank McKinnell, chairman and CEO of Pfizer. "The acquisition of Pharmacia will give us an even stronger global platform...

Read the rest of this article with a Free Trial at HighBeam Research.

Premium Content Partnership | HighBeam Research provides an in-depth online archive library of reference works.